Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Deficient Smad7 expression: a putative molecular defect in scleroderma.

Chunming Dong1, Shoukang Zhu, Tao Wang

  • 1Division of Cardiology, Duke University Medical Center, 7504 Duke Hospital North, Box 3845, Durham, NC 27710, USA.

Proceedings of the National Academy of Sciences of the United States of America
|March 21, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Echocardiographic characterization of combined postcapillary and precapillary pulmonary hypertension in systemic sclerosis with preserved ejection fraction.

Echo research and practice·2026
Same author

The role of microRNAs in cardiovascular disease associated with the consumption of ultra-processed foods: a comprehensive review.

Frontiers in nutrition·2026
Same author

Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis.

Annals of the rheumatic diseases·2026
Same author

Identification of Risk Factors for Incident Left Ventricular Systolic Dysfunction and Predictors of Cardiac Recovery in Patients With Systemic Sclerosis.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

The Effect of Pulmonary Function Test Reference Equations on Classification of Restrictive Lung Disease Severity in Systemic Sclerosis.

Arthritis care & research·2025
Same author

Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis.

BMJ (Clinical research ed.)·2025

Scleroderma involves fibrosis linked to transforming growth factor-beta (TGF-β) signaling. Reduced Smad7 and increased Smad3 in scleroderma fibroblasts cause TGF-β hyperresponsiveness, which Smad7 gene therapy can correct.

Area of Science:

  • Connective tissue diseases
  • Molecular biology
  • Cell signaling

Background:

  • Scleroderma is a chronic systemic disease characterized by organ fibrosis.
  • Transforming growth factor-beta (TGF-β) signaling is implicated in scleroderma pathogenesis.
  • Smad proteins are key intracellular mediators of TGF-β signaling.

Purpose of the Study:

  • To investigate TGF-β pathway signaling components and activity in scleroderma.
  • To examine Smad protein expression and function in scleroderma fibroblasts.
  • To determine if Smad7 deficiency contributes to TGF-β hyperresponsiveness in scleroderma.

Main Methods:

  • Analysis of Smad protein expression in scleroderma skin and cultured fibroblasts.
  • Assessment of TGF-β-induced signaling events (Smad phosphorylation, PAI-1 transcription) in scleroderma fibroblasts.

Related Experiment Videos

  • In vitro adenoviral gene transfer of Smad7 into scleroderma fibroblasts.

    • Main Results:

    • Scleroderma fibroblasts exhibit decreased Smad7 and increased Smad3 expression compared to normal fibroblasts.
    • TGF-β signaling, including Smad2/3 phosphorylation and PAI-1 gene transcription, is enhanced in scleroderma fibroblasts.
    • Adenoviral delivery of Smad7 normalized TGF-β signaling in scleroderma fibroblasts.

    Conclusions:

    • Alterations in the Smad pathway, specifically Smad7 deficiency and Smad3 upregulation, contribute to TGF-β hyperresponsiveness in scleroderma.
    • Smad7 replacement therapy shows potential for restoring normal TGF-β signaling in scleroderma.
    • These findings elucidate a molecular mechanism underlying scleroderma pathogenesis.